TrialSignal transduction and targeted therapy2025

Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02).

Hong Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.